about
A systematic evaluation of factors associated with nocturia--the population-based FINNO studyLifestyle counseling in overweight truck and bus drivers - Effects on dietary patterns and physical activityAS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in FinlandNo serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland.Childhood narcolepsy with cataplexy: comparison between post-H1N1 vaccination and sporadic cases.Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination.Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.Polysomnographic and actigraphic characteristics of patients with H1N1-vaccine-related and sporadic narcolepsy.HLA-DPB1 and HLA class I confer risk of and protection from narcolepsyNeuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination.Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus.Self-evaluations of factors promoting and disturbing sleep: an epidemiological survey in Finland.Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland.The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.Clinical and polysomnographic course of childhood narcolepsy with cataplexy.Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation.Periodic limb movements in sleep are followed by increases in EEG activity, blood pressure, and heart rate during sleep.The impacts of nitrous oxide gas on sleep quality during alcohol withdrawal.Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trialPsychosis in patients with narcolepsy as an adverse effect of sodium oxybate.Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns.Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics.Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial.Heritability and mortality risk of insomnia-related symptoms: a genetic epidemiologic study in a population-based twin cohort.Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.Sleep and mortality: a population-based 22-year follow-up study.Associations of reported bruxism with insomnia and insufficient sleep symptoms among media personnel with or without irregular shift work.Morning cortisol levels and perceived stress in irregular shift workers compared with regular daytime workers.Hypocretin-1 Levels Associate with Fragmented Sleep in Patients with Narcolepsy Type 1State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome.Challenging issues: sleep-wake, augmentation and quality of life.Developing ICF Core Sets for persons with sleep disorders based on the International Classification of Functioning, Disability and Health.Trends in self-reported sleep duration and insomnia-related symptoms in Finland from 1972 to 2005: a comparative review and re-analysis of Finnish population samples.Effects of exercise and diet interventions on obesity-related sleep disorders in men: study protocol for a randomized controlled trial.Nocturnal systolic blood pressure is increased in restless legs syndrome.Sleep duration, lifestyle intervention, and incidence of type 2 diabetes in impaired glucose tolerance: The Finnish Diabetes Prevention Study.Effect of Six-Month Diet Intervention on Sleep among Overweight and Obese Men with Chronic Insomnia Symptoms: A Randomized Controlled Trial.Epidemiology of sleep disorders.Part 1. International Classification of Functioning, Disability and Health (ICF) Core Sets for persons with sleep disorders: results of the consensus process integrating evidence from preparatory studies.European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society.
P50
Q24289211-B79CD957-4629-4040-93A9-B70AB4E80EDCQ28387343-7BF57CDE-5333-4B33-8637-761699A5949BQ28730881-26C95C5F-E544-42F7-B102-1AB3D6FB124FQ30352889-F6FD72F4-7643-466B-8B19-0309A24C80A6Q30358373-ECD59A62-44E2-4D91-9BC8-54FB09C4A387Q30362783-A1968E94-5FDD-4831-9605-6C52AFCCD8B7Q30369654-F9D49785-8651-49B6-960C-AB6CEF1D600CQ30370364-1FE7E736-6B8E-4784-B531-7DE2078205C8Q30370632-0DDD3156-1586-473F-B133-CF9A10475816Q30375856-6780CF35-2343-4C2C-A130-87EC89F5AAABQ30377352-6FBE8C1C-19A5-430D-943F-C9BA9B3BC80EQ30404654-D428A999-92C5-4443-B119-08459C04EF93Q30414919-C11F1293-0721-4BCC-AC37-685D253097B6Q30424863-4D64F780-6788-4186-8800-195E8055173DQ30559262-4458119B-A170-4B19-AD4F-FFCF4F4ED680Q30582000-B44DE2CA-5BDD-4AFD-B9E3-903E9AB99154Q33586220-2A047234-79D9-47CA-B379-23C1BD8D7224Q33864282-8801083F-7890-4D7C-A3B1-FE09377ACAFCQ33887975-7167A0D8-A07B-46AE-B5A4-6EC6F1F8695BQ34068000-7CC470C2-49BA-432C-87A3-07E3BABA7C30Q34144175-717CA973-7E2F-4302-848B-213B3A3D8841Q34581884-625A0BAB-BDDD-4ED7-BAE8-FB46F3F3F1EAQ34599328-DD097AAD-D282-412A-A495-935004972032Q35059220-78D3387D-893B-4493-8725-21CB281F1089Q36018973-C2D68C55-235E-4A38-9912-637E949FE2D5Q36493219-E20ADB9F-88CF-43E4-AEBF-B7D070AF2AD0Q36537784-0B35FDB7-C58B-4219-9E29-11E6842C9D26Q36635455-1A3EC076-0D30-40C3-B59F-B022F0510067Q36808742-AD45EB3F-3B75-4463-9991-83362B1669F9Q36827987-0905A3FC-AD4E-4D2B-B725-80D1A03FD1CEQ36846880-C5C39DA7-E675-4FA3-954E-D17CECEE30BEQ36888416-9143C0D7-00EE-435A-8F87-7CD7A130CB01Q37084935-1494D24C-22B4-4824-B62F-FC809D6C2456Q37113580-26D60EA3-8143-471A-BC25-2E91C29F11C4Q37242940-AD880BD4-D39B-463C-A18F-CDF361E52D2BQ37400889-B00E897D-679C-4E81-870E-345B58E64B63Q37463435-35EA5EB9-29F7-49FB-A3D8-6191EE95D2C6Q37807675-39E064F4-E68C-4338-9BD8-A3F7E1CC41D2Q37810693-86869674-4CCF-422A-AEBA-0563E5605305Q38039480-CA0D18D4-5851-426C-A502-F0BBFC50AE68
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Markku Partinen
@ast
Markku Partinen
@en
Markku Partinen
@es
Markku Partinen
@nl
Markku Partinen
@sl
type
label
Markku Partinen
@ast
Markku Partinen
@en
Markku Partinen
@es
Markku Partinen
@nl
Markku Partinen
@sl
prefLabel
Markku Partinen
@ast
Markku Partinen
@en
Markku Partinen
@es
Markku Partinen
@nl
Markku Partinen
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0002-8182-9368
P7859
lccn-n88185592